AtriCure (NASDAQ:ATRC – Get Free Report) is expected to be posting its Q2 2026 results after the market closes on Thursday, July 23rd. Analysts expect the company to announce earnings of $0.03 per share and revenue of $151.8040 million for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, July 23, 2026 at 4:30 PM ET.
AtriCure Price Performance
ATRC stock opened at $34.77 on Tuesday. The company has a market capitalization of $1.76 billion, a P/E ratio of -347.70 and a beta of 1.24. The company has a fifty day moving average price of $29.52 and a 200-day moving average price of $31.52. The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.18 and a current ratio of 4.29. AtriCure has a 52-week low of $25.36 and a 52-week high of $43.18.
Insider Buying and Selling
In other AtriCure news, Director Karen Prange sold 3,000 shares of the stock in a transaction dated Wednesday, May 20th. The stock was sold at an average price of $28.65, for a total transaction of $85,950.00. Following the completion of the sale, the director directly owned 26,373 shares in the company, valued at approximately $755,586.45. This trade represents a 10.21% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 4.00% of the company’s stock.
Institutional Investors Weigh In On AtriCure
Analysts Set New Price Targets
A number of research firms recently weighed in on ATRC. Weiss Ratings downgraded AtriCure from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, May 4th. Zacks Research downgraded AtriCure from a “strong-buy” rating to a “hold” rating in a report on Thursday, June 4th. Freedom Capital upgraded AtriCure to a “strong-buy” rating in a research report on Wednesday, April 1st. Canaccord Genuity Group increased their price target on AtriCure from $53.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Finally, Wall Street Zen downgraded AtriCure from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 2nd. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $48.71.
Read Our Latest Stock Report on AtriCure
About AtriCure
AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.
The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.
Featured Articles
- Five stocks we like better than AtriCure
- The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence
- Is Domino’s Stock Serving Up a Buying Opportunity?
- A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free
- Why Gold Miners Could Be the Market’s Biggest Comeback Story
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.
